380610-27-5
Post Buying Request-
-
Basic information
- Product Name: Pertuzumab
- Synonyms: pertuzumab;2C4;Immunoglobulin G1, anti-(human V (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer;Omnitarg;Unii-K16aiq8ctm
- CAS NO:380610-27-5
- Molecular Formula: C17H27NO2
- Molecular Weight: 277.40178
- EINECS: N/A
- Product Categories: N/A
- Mol File: 380610-27-5.mol
- Article Data: 0
-
Chemical Properties
- Melting Point: N/A
- Boiling Point: N/A
- Flash Point: N/A
- Appearance: /
- Density: N/A
- Refractive Index: N/A
- Storage Temp.: N/A
- Solubility: N/A
- CAS DataBase Reference: Pertuzumab(CAS DataBase Reference)
- NIST Chemistry Reference: Pertuzumab(380610-27-5)
- EPA Substance Registry System: Pertuzumab(380610-27-5)
-
Safety Data
- Hazard Codes: N/A
- Statements: N/A
- Safety Statements: N/A
- WGK Germany:
- RTECS:
- HazardClass: N/A
- PackingGroup: N/A
- Hazardous Substances Data: 380610-27-5(Hazardous Substances Data)
380610-27-5 Suppliers
Recommended suppliersmore
380610-27-5 Usage
Description
Pertuzumab is an anti-human epidermal growth factor receptor 2 (HER2) antibody that was approved by the US FDA in June 2012 for use in combination with trastuzumab (Herceptin?) and docetaxel chemotherapy for the treatment of people with HER2-positive (HER2+) metastatic breast cancer (mBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Pertuzumab inhibits HER2 dimer formation with other HER members, such as HER1 and HER3, thus inhibiting the downstream signaling processes associated with tumor growth and progression. Pertuzumab is the first HER2 dimerization inhibitor to reach the market. The mechanism of actions of trastuzumab and pertuzumab are believed to complement each other and provide a more comprehensive inhibition of tumor growth than either agent alone. Preclinical data showed that the combination of trastuzumab and pertuzumab has a strongly enhanced antitumor effect and induces tumor regression in xenograft models, something that cannot be achieved by either monotherapy alone.Uses
Anti-neoplastic.Brand name
PerjetaClinical Use
Monoclonal antibody: Treatment of HER2 receptor +ve breast cancerDrug interactions
Potentially hazardous interactions with other drugs None knownMetabolism
Antibodies are cleared mainly by catabolism.Check Digit Verification of cas no
The CAS Registry Mumber 380610-27-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,8,0,6,1 and 0 respectively; the second part has 2 digits, 2 and 7 respectively.Calculate Digit Verification of CAS Registry Number 380610-27:
(8*3)+(7*8)+(6*0)+(5*6)+(4*1)+(3*0)+(2*2)+(1*7)=125
125 % 10 = 5
So 380610-27-5 is a valid CAS Registry Number.
380610-27-5Upstream product
380610-27-5Downstream Products
Post a RFQ
1
What can I do for you?
Get Best Price
Get Best Price for 380610-27-5
Pertuzumab
